Sean O'Bryan
No más puestos en curso
Perfil
Sean O'Bryan worked as the Director of Regulatory Affairs at Genzyme Corp.
from 2006 to 2014.
He then served as the Senior Director of Regulatory Affairs at bluebird bio, Inc. from 2014 to 2015.
From 2016 to 2018, he was the VP and Head of Regulatory Affairs & Quality Assurance at Lysogene SA. Mr. O'Bryan then held the position of SVP and Head of Regulatory Affairs & Quality Assurance at Sio Gene Therapies, Inc. from 2018 to 2020.
He later became the Senior Vice President and Head of Regulatory Affairs at Freeline Therapeutics Ltd.
from 2020 to 2022.
Prior to his career in the industry, Mr. O'Bryan obtained his undergraduate degree from Boston University.
Antiguos cargos conocidos de Sean O'Bryan.
| Empresas | Cargo | Fin |
|---|---|---|
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Consejero General | 01/01/2022 |
| SIO GENE THERAPIES INC. | Public Communications Contact | 01/11/2020 |
| LYSOGENE | Consejero General | 01/12/2018 |
| BLUEBIRD BIO, INC. | Consejero General | 01/10/2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Consejero General | 01/08/2014 |
Formación de Sean O'Bryan.
| Boston University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| LYSOGENE | Commercial Services |
| BLUEBIRD BIO, INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Sean O'Bryan
